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Received October 22, 2012; accepted November 2, 2012AbstractThe model for end-stage liver disease (MELD) has replaced the role of the ChildeTurcotteePugh system as a more commonly used system
in evaluating the severity of liver dysfunction in patients with chronic liver disease, owing to its superior ability to predict survival. The United
Network of Organ Sharing (UNOS) in the USA has used the MELD system for prioritizing donor grafts in advanced cirrhotic patients awaiting
liver transplantation since 2002. Serum sodium level is another important prognostic predictor in cirrhosis. Consequently, by incorporating
serum sodium into the original MELD, the MELD-Na, MELDNa, the MELD-to-sodium ratio (MESO) index, and the ReFit MELDNa were
proposed in an attempt to improve the predictive ability of the original MELD. Nevertheless, there are some limitations of the MELD-based
systems that need to be refined. The MELD-based systems merely use laboratory data as parameters for the equation, therefore, any lack in
unification and standardization of laboratory methods will result in inconsistent data that affect the prioritization of liver transplantation.
Furthermore, the MELD system includes creatinine as a parameter, and serum creatinine level may represent different degrees of renal
dysfunction in men and women. Therefore, these limitations may compromise the fair process of organ allocation for female cirrhotic patients.
Currently, the application of the MELD system has been extended to tumor staging of hepatocellular carcinoma. Several studies have replaced
the ChildeTurcotteePugh system with the MELD as a parameter, indicating that the use of different criteria of liver dysfunction in cancer
staging may enhance prognostic accuracy. Although the outcome data of the modified staging systems need to be confirmed, the concept of using
the MELD as a reference system for evaluating the severity of liver dysfunction has globally become an important issue.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Chronic liver inflammation, a consequence of chronic virus
infection or alcohol consumption, may subsequently develop
into liver cirrhosis arising from continuous liver injury.
Advanced liver cirrhosis may present with ascites formation,
coagulopathy, elevated serum bilirubin level, decreased serum
albumin level, presence of hepatic encephalopathy, and* Corresponding author. Dr. Teh-Ia Huo, Department of Medicine, Taipei
Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan,
ROC.
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http://dx.doi.org/10.1016/j.jcma.2013.04.010cirrhotic cardiomyopathy.1,2 Deterioration of these clinical
parameters may indicate liver failure and contributes to a
major cause of death in patients with liver cirrhosis.3 The
ChildeTurcotteePugh (CTP) system was initially used to
evaluate the severity of liver dysfunction and predict survival
in these chronic liver disease patients (Table 1).4 The model
for end-stage liver disease (MELD) scoring system was pro-
posed as the major system for organ allocation in cirrhotic
patients awaiting liver transplantation, owing to its better
ability to predict accurately short-term outcome compared
with the CTP system.5 In recent years, many study groups
have tried to enhance the prognostic ability of the MELD
system by incorporating new parameters or adjusting thehinese Medical Association. All rights reserved.
Table 1




CTP Discrete Bilirubin, INR, PT prolongation,
ascites, encephalopathy
d e
MELD Continuous 9.57  loge Cr þ 3.78  loge
bilirubin þ 11.2  loge INR þ 6.43
All variables: minimal values set
as 1; Cr: bounded above by 4 mg/dL
Corrected the subjective influence
of the CTP system with a continuous
model
MELD-Na Continuous MELD þ 1.59  (135 e Na) Na: between 120 and 135 mEq/L
Others same as MELD
Added the influence of hyponatremia
to the original MELD
MELDNa Continuous MELD þ (140 e Na)  [0.025 
MELD  (140 e Na)]
Na: between 125 and 140 mEq/L
Others same as MELD
Added the influence of hyponatremia
to the original MELD, adjusted the
overcorrection of hyponatremia with
high MELD scores
MESO index Continuous (MELD/Na)  10 Same as MELD To amplify the opposing effect of the
MELD and Na
ReFit MELDNa Continuous 4.258  loge bilirubin þ 6.792 
loge Cr þ 8.29  loge INR þ
0.652  (140eNa)  0.194 
(140eNa)  bilirubinc þ 6.327
Bilirubin: bounded below by 1 mg/dL
Cr: between 0.8 and 3 mg/dL. Patients
receiving renal replacement therapy
were assigned Cr as 3 mg/dL.
INR: between 1 and 3
Na: between 125 and 140 mEq/L
Bilirubinc: between 1 and 20
Adjusted the weight of each variable,
changed the upper and lower bound
of the parameters, added the influence
of hyponatremia and adjusted the
overcorrection of hyponatremia with
high serum bilirubin to the original
MELD.
DMELD Continuous (Second MELD score  initial
MELD score)/ interval period of time
Same as MELD Corrected the single point determination
of score in MELD and highlighted on
the change of score over time.
The units for every parameter are as follows: Cr, mg/dL; bilirubin/bilirubinc, mg/dL; Na, mEq/L; time, months.
Cr ¼ creatinine; CTP ¼ ChildeTurcotteePugh; INR ¼ international normalized ratio; MELD ¼ model for end-stage liver disease; MESO ¼ MELD-to_Na ratio;
Na ¼ sodium; PT ¼ prothrombin time.
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MELD system have been extended beyond its original pur-
pose. In this review article, we highlight the development of
the MELD and MELD-derived systems, the clinical applica-
tions in organ allocation and other purposes, and associated
limitations and future perspectives.2. Development of MELD system
As a consequence of continuous liver insult due to chronic
inflammation, limited treatment options are effective for pa-
tients with advanced cirrhosis. In recent decades, liver trans-
plantation has become the only definite treatment for advanced
cirrhosis with the possibility of cure. Even so, major challenges
in the shortage of liver donor grafts have limited its priority in
clinical practice. In order to optimize organ allocation to patients
in utmost need (the “sickest first” policy), systems for evaluating
the outcome of these patients on the transplantation list have
been developed. The MELD scoring system was initially pro-
posed in 2000 to predict mortality in cirrhotic patients under-
going transjugular intrahepatic portosystemic shunt.6 The
MELD scoring system provided continuous values by a loga-
rithmic calculation of three laboratory-available parameters,
serum bilirubin, international normalized ratio (INR) of pro-
thrombin time, and creatinine level (Table 1). A major break-
through of the MELD system was the introduction of renal
function into the prognostic model. Renal dysfunction is often
seen in patients with liver cirrhosis and the development of
hepatorenal syndrome is a consequence of deteriorated residualliver function in advanced cirrhotic patients.7 Profound renal
dysfunction usually indicates an extremely poor prognosis in
these patients.8 Therefore, incorporation of serum creatinine
may further enhance its prognostic ability. Notably, the MELD
had been implemented as the major reference system for organ
allocation in liver transplantation by the United Network of
Organ Sharing (UNOS) in the USA to prioritize advanced
cirrhotic patients, due to its better ability to predict survival in
comparison with the CTP classification.5 The MELD system
had several clear advantages over the CTP classification. First, it
only includes objective parameters that eliminate interobserver
bias. In addition, compared to the CTP classification, MELD
provides larger grading scales that assist in better discrimination
of the severity of liver dysfunction, owing to its status as a
continuous entity. After 2002, ample evidence subsequently
confirmed the prognostic role of the MELD system in different
clinical settings.3. Proposal of the MELD-derived systems: making the
MELD better
Since the introduction of the MELD system, many study
groups have developed modified systems derived from the
original MELD to enhance its prognostic ability. Serum sodium
(Na) level has been recognized as an important prognostic
indicator in cirrhosis, and hyponatremia is often associated
with portal hypertension, ascites formation, hepatorenal syn-
drome, and liver-related mortality.9e12 Arising from the added
effect of hyponatremia on the risk of death in cirrhotic patients,
421Y.-H. Lee et al. / Journal of the Chinese Medical Association 76 (2013) 419e424the MELD-Na was proposed in 2006 (Table 1).13 The MELD-
Na incorporated serum Na into the equation by adding addi-
tional scores to the original MELD in patients with serum Na
between 120 mEq/L and 134 mEq/L. The MELD-Na priori-
tizes hyponatremia patients on the transplantation list over
those with the same MELD score but with normal serum Na
level. With the incorporation of serum Na level, MELD-Na
could more accurately predict the survival of cirrhotic pa-
tients and shorten the waiting time on the transplant list.
However, there are still some limitations with the MELD-Na
system, and an important issue is that the role of hypona-
tremia on the added risk of death is abolished with the increase
of MELD score. Kim et al have proposed the MELDNa and
corrected this limitation by incorporating serum Na to the
original MELD equation; the MELDNa also eliminates the
effect of hyponatremia on the risk of death in patients with high
MELD scores (Table 1).14 The MELD-to-sodium ratio
(MESO) index was proposed by our study group to amplify the
opposing effect of MELD score and serum Na in survival
prediction (Table 1). The MESO index provides better prog-
nostic ability when compared with the original MELD system,
and it also correlates well with hepatic venous pressure
gradient and CTP score.15 The ReFit MELDNa was introduced
in 2011 by emphasizing the major key points described by
previous equations (Table 1).16 Similarly, it uses serum bili-
rubin, INR of prothrombin time and serum creatinine as the
basis of the equation. First, it optimizes the coefficients and the
upper and lower bounds of the three parameters according to
the linear relationship in the Cox model with the risk of death.
Second, it incorporates serum Na into the equation to enhance
the prognostic ability in patients with hyponatremia. Lastly, the
decreased impact of serum Na on mortality when serum bili-
rubin increases is also considered and is described in the
equation. The ReFit MELDNa more accurately discriminates
the mortality of patients on the waiting list when compared
with the original MELD and MELDNa; it has ultimately
affected up to 12% of patients on the transplantation list.16
Alternatively, previous studies have focused on the degree
of liver dysfunction by a single-point determination of the
score but have neglected the continuous change in MELD score
throughout the course of the disease. The change in MELD
score over time (DMELD) has previously been proposed and
defined as the change in MELD score per interval period of
time (months) (Table 1).17 An increasing DMELD score is
associated with the onset of ascites and hepatic encephalopathy
and is superior to the initial MELD and CTP scores in pre-
dicting intermediate outcome in advanced cirrhotic patients.18
Many complications may accompany the ongoing deterio-
ration of residual liver function and the development of
eventual hepatic failure. Intractable hepatic encephalopathy,
bleeding esophageal varices, spontaneous bacterial peritonitis,
and ascites formation are major complications in cirrhosis and
are also important prognostic predictors in these patients.
Supporting evidence shows that the complications in these
patients may not necessarily correlate well with the MELD
score,19,20 suggesting that these patients may be potentially
missed in the MELD era. Studies have shown that with theincorporation of hepatic encephalopathy21 and ascites forma-
tion,22 the modified MELD systems would enhance predictive
ability independent of the MELD score.
4. Limitations of the MELD and MELD-derived systems
Despite the suggestion that MELD-derived systems could
more accurately predict survival and discriminate the severity
of liver dysfunction when compared with the CTP system,
there are still some real drawbacks to this proposition. The
MELD-derived systems exclusively rely on objective labora-
tory data, and variations in laboratory methods potentially
affect its accuracy. The compensated kinetic Jaffe, O’Leary
modified Jaffe, enzymatic, and standard kinetic Jaffe methods
have been used to measure serum creatinine. There is negli-
gible agreement among these different assays in the mea-
surement of serum creatinine for the calculation of MELD
score.23 Furthermore, between-laboratory variations in INR
measurement may result in substantial changes in the MELD
score independent of the severity of illness, and may signifi-
cantly affect prioritization for liver transplantation.24 Further
laboratory methods should be united and standardized in the
future in an attempt to facilitate a fair process of organ allo-
cation. Another limitation of the MELD-derived systems is
that the serum creatinine may represent different degrees of
renal dysfunction between the sexes. Women have lower
glomerular filtration rate than men for the same serum creat-
inine value, yet this is not accounted for in the MELD and
MELD-derived systems.25 Using the same serum creatinine
level for calculating the MELD score lowers the prioritization
for liver transplantation for female cirrhotic patients. There-
fore, a corrected-creatinine MELD system was developed in
an attempt to adjust creatinine level to the same glomerular
filtration rate in female patients as in male patients. This pri-
oritizes female patients for liver transplantation, but may only
be justified in predicting intermediate-term (9- and 12-month),
but not short-term (3- and 6-month) mortality.26
Despite its drawbacks and the proposal of many other
MELD-derived systems, the original MELD system is still the
major organ allocation system for liver transplantation used in
most countries. The main reason is that the MELD system
avoids interobserver bias with only objective parameters in the
equation; however, some other studies comparing the superi-
ority of the different MELD-derived systems have suggested
inconsistent results.27e30 In Taiwan, an endemic area for
hepatitis B, the MELD system is also the system used to
prioritize patients for liver transplantation. Although the
outcome data of patients on the transplantation list by using
the MELD allocation system in Taiwan still need to be
investigated, this strategy provides a fair process of allocating
donor organs without taking the personal decisions of physi-
cians into consideration.
5. MELD in hepatocellular carcinoma
Currently, the application of the MELD system has been
expanded to an extent beyond its original design. A substantially
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hepatocellular carcinoma (HCC), therefore, the MELD-derived
systems played a crucial role in outcome prediction in HCC
patients in terms of evaluating the degree of liver dysfunction in
addition to tumoral factors.31e33 The Barcelona Clinic Liver
Cancer (BCLC),34,35 Cancer of the Liver Italian Program
(CLIP),36 and Japan Integrated Scoring (JIS)37 are all tumor
staging systems for HCC and all include CTP classification as a
parameter of representing liver function. We have modified the
BCLC,CLIPand JIS classification systems by replacing theCTP
classification to the MELD scores in evaluating the functional
liver reserve of HCC patients (Table 2).38 The MELD-based
CLIP and MELD-based JIS staging systems have improved
overall prognostic ability when compared with the original
systems. More recently, we have developed a new tumor staging
system by incorporating different combinations of prognostic
predictors, including tumoral factors [total tumor volume, liver
function (CTP, MELD, MELDNa and MELD-Na) and tumor
behavior (presence of vascular invasion and serum a-fetoprotein
level)] and compared them with the original BCLC, CLIP, JIS,
and Tokyo staging systems and each other in terms of outcome
prediction. The Taipei Integrated Scoring System,27 which en-
compasses total tumor volume, CTP and serum a-fetoprotein
level as parameters, displayed the best prognostic ability when
compared with the original systems and other combinations in
terms of outcome prediction (Table 2).33 Although further pro-
spective studies are needed to validate the role ofMELD in HCC
staging, the notion of the MELD to replace the CTP as the
parameter representing liver functional reserve may change
future management guidelines for HCC.39Table 2


























Modified BCLC Fulfill criteria
of each stage
v
CLIP Sum of scores v
Modified CLIP Sum of scores v
JIS Sum of scores v
Modified JIS Sum of scores v
TIS Sum of scores v
AFP ¼ a-fetoprotein; BCLC ¼ Barcelona Clinic Liver Cancer; CLIP ¼ Cancer o
Cooperative Oncology Group; HCC ¼ hepatocellular carcinoma; JIS ¼ Japan In
Integrated System; TTV ¼ total tumor volume.6. Future perspectives
The MELD system was created to optimize the allocation
of donor organ grafts in advanced cirrhotic patients awaiting
liver transplantation, due to its enhanced ability in predicting
short-term outcome. However, the role in predicting post-
transplant mortality was not considered and established
when developing such systems in organ allocation. The MELD
system did not well correlate with post-transplant mortality in
patients receiving transplantation.40 General health condition,
other chronic comorbidity and most importantly, donor fac-
tors, all may have an impact on post-transplant mortality.
Systems for selecting the highest pretransplant mortality and
lowest post-transplant mortality should be developed to opti-
mize the allocation of organs to those who are most in need,
and will have the maximal benefit upon receiving the organ.
The MELD system has now expanded its clinical in-
dications beyond its original use. An important issue that may
require further attention is that the MELD system was origi-
nally created in patients who did not have acute or reversible
complications. Therefore, the MELD score would more pre-
cisely represent the current liver function status after treating
the acute complications that develop in these patients.
Whether the MELD system and its derived models can be
equally applied as a tool for outcome prediction in different
clinical scenarios beyond their original aim requires additional
study for further clarification.
Although the MELD system is considered to represent
more accurately liver dysfunction in terms of outcome pre-
diction, the CTP is still the main system in evaluating theic predictors for HCC patients Stages
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f the Liver Italian Program; CTP ¼ ChildeTurcotteePugh; ECOG ¼ Eastern
tegrated Scoring; MELD ¼ model for end-stage liver disease; TIS ¼ Taipei
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Results from recent studies have demonstrated enhanced ac-
curacy of predicting long-term outcome in HCC patients by
replacing the CTP system with the MELD system.38 Addi-
tional prospective studies should be performed to validate the
role of the MELD system in HCC, and management guidelines
for HCC may need to be modified to provide optimal rec-
ommendations for cancer patients.References
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